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Aims: Diabetes mellitus has been reported to be one of the most prevalent comorbidity in
patients with Coronavirus Disease 2019 (COVID-19). We aimed to assess the association of
comorbid diabetes with COVID-19 severity or mortality in China.
Methods: We performed a systematic literature search from six electronic databases on dia-
betes and COVID-19. The outcome of interest was disease severity or mortality. Hetero-
geneity among the studies was assessed by the Cochran Q test and the I2 statistic. A
random effects model was applied to calculate the pooled risk ratio (RR) with 95% confi-
dence interval (CI).
Results: Nine studies from different provinces/cities were identified according to the prede-
fined inclusion and exclusion criteria. There were a total of 1070 patients with diabetes, out
of the 8807 COVID-19 cases. The majority of the cases were derived from Hubei Province. A
low degree of heterogeneity in the risk estimates was observed in the included studies.
Meta-analysis showed that there was a significant association of preexisting diabetes with
disease severity or death. The pooled RR was 2.96 (95% CI: 2.31–3.79; p < 0.001). Sensitivity
analysis demonstrated no significant changes in the pooled estimates.
Conclusions: Comorbid diabetes was associated with an increased risk of disease severity or
death in Chinese COVID-19 patients.
 2020 Elsevier B.V. All rights reserved.in China in December 2019, and has now rapidly evolved as
1. Introduction
An unprecedented Coronavirus Disease 2019 (COVID-19),
caused by a novel beta-coronavirus Severe Acute RespiratorySyndrome Coronavirus-2 (SARS-CoV-2) [1], was first reported
a global pandemic [2]. WHO has declared COVID-19 a public
health emergency of international concern [3]. By May 30,China.
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 4 62020, there have been 5,819,962 confirmed cases and 362,786
deaths reported worldwide [3].
The COVID-19 patients experience a wide spectrum of
clinical severity, ranging from mild to severe or fatal [4]. A
growing body of evidence suggests that the variability in clin-
ical patterns could partly be attributable to their underlying
comorbidity [5]. Studies from China [4,6–8] found that dia-
betes mellitus was the second most prevalent comorbidity
of COVID-19, and people with diabetes appeared to be likely
to have worse clinical outcomes than those without the con-
dition. A recent study observed that the overall case-fatality
rate was 7.3% among those patients with preexisting comor-
bid diabetes [9].
To date, there are several meta-analyses [10–14] exploring
the association of comorbidity including diabetes with dis-
ease severity or death. However, none of these meta-
analyses calculated the risk ratio of severity or mortality
between patients with diabetes versus those without dia-
betes. More importantly, some studies included in the meta-
analyses were size-limited reports predominantly from HubeiRecords identified through 
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Fig. 1 – Flow diagram depicting the literature search and selecti
criteria, a total of nine studies were included in the final meta-Province and potential overlapping of patients across the
included studieswas not considered, which could have biased
the estimates. Along with the latest studies published, espe-
cially those outside Hubei Province, we are able to perform
an updated analysis to better examine the association of
comorbid diabetes with COVID-19 severity or mortality in
China.
2. Methods
2.1. Search strategy
We performed a systematic literature search through data-
bases PubMed, Web of Knowledge, medRxiv, and bioRxiv for
English-language literatures, the China National Knowledge
infrastructure (CNKI) and the Wanfang database for
Chinese-language publications. The Medical Subject Heading
(MeSH) terms and/or key words included ‘‘COVID-19” OR
‘‘SARS-CoV-2” OR ‘‘2019-nCoV” AND ‘‘Diabetes” AND ‘‘China”
(or each name of the 31 provinces/ municipalities/ autono-09)
 = 9)
xcluded (n = 53) based on:
ically covered/overlapped with 
ies (n = 34)
me information grouped by diabetes 
ber of cases <30 (n = 5)
n pediatric populations (n = 1)
s removed (n = 16)
xcluded based on abstracts (n = 247)
on strategy. After applying the inclusion and exclusion
analysis.
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d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 4 6 3mous regions in mainland China). Titles and abstracts of the
resulting literatures were screened for further review. The
references of identified literatures were checked as well if
needed. Only original studies were considered for the
review. Duplicate and overlapping publications were
excluded. Two authors (YZ and CW) independently did the
literature search. Any disagreementswere resolved after dis-
cussion. This study was conducted following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guideline.
2.2. Eligibility criteria
We included all research articles in adult patients diagnosed
with COVID-19; with direct or indirect information on the
outcome of disease severity or mortality grouped by comor-
bid diabetes; conducted in Mainland China and published
between January 01 and May 30, 2020. The following types
of article were excluded: total number of cases below 30;
articles other than original research (review articles, letters,
or commentaries); case reports and series; articles on pedi-
atric populations; geographically covered by/overlapped
with other studies.
2.3. Data extraction
Data were extracted using a standardized data collection
form. Information was extracted from each included article,
including the first author, inclusion date of patients, study
location, study design, gender, age, sample size, comorbid
diabetes, and disease severity/mortality. Severe COVID-19
cases were defined if patients had indication of respiratory
rate >30 breaths/min, or SpO2 %  93% on room air, or
PaO2/FiO2  300 mmHg, or critical complication (respiratory
failure, septic shock, and or multiple organ dysfunction/fail-
ure) [15].
2.4. Statistical analysis
Meta-analysis was conducted in order to evaluate the asso-
ciation of comorbid diabetes with disease severity/mortality.
Heterogeneity among the studies was assessed by the
Cochran Q test and the I2 statistic. An I2 value 25% indi-
cates a low degree of heterogeneity [16]. The pooled risk
ratio (RR) with 95% CI in the forest plot was analyzed using
a random effects model (Mantel-Haenszel method) irrespec-
tive of the heterogeneity. Begg’s funnel-plot analysis was
performed to qualitatively assess the risk of publication bias
[17]. In addition, a sensitivity analysis was performed using
the sequential omission of individual studies to assess the
quality and consistency of the results. All analyses were per-
formed using R (version 3.6.2, www.r-project.org). A two-
tailed p value <0.05 was considered statistically significant
in all analyses.
3. Results
Initial search yields 325 records, and 309 records remained
after the removal of duplicates. After screening the abstractsT
4 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 4 6247 records were excluded. After evaluating 62 full-text arti-
cles for eligibility, 53 full-text articles were further excluded.
Finally, 9 studies from different provinces/cities [6,18–25] were
included in the meta-analysis (Fig. 1).
The basic characteristics of the patients in the identified 9
studies are presented in Table 1. Overall, the patients were
enrolled between Dec.30, 2019 and Mar.20, 2020. Men
accounted for 48.1% of the included cases. The median age
was 44–61 years. Death information grouped by diabetes sta-
tus was only available in one study from Hubei, whereas dis-
ease severity as the outcome was used in the other eightStudy
Random effects model
Heterogeneity: I 2  = 23%, τ2  = 0.0311, p = 0.23
Zhu et al., 2020
Zheng et al., 2020
Yuan et al., 2020
Huang et al., 2020
Wei et al., 2020
Cao et al., 2020
Cai et al., 2020
Fan et al., 2020
Liao et al., 2020
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Fig. 2 – Forest plot showing the association of preexisting diabe
horizontal lines indicate the lower and upper limits of the 95% C
of each study in the meta-analysis. RR: risk ratio.
Fig. 3 – Funnel plots for detecting publication bias. The X-axis r
represents the standard error.studies. Moreover, 83.3% of the cases were derived from Hubei
Province, which is proportional to the latest national data
(82.1%) [26].
There were a total of 1070 patients with diabetes, out of
the 8807 COVID-19 cases. There was a low degree of hetero-
geneity (p = 0.235 in Cochran’s Q test, I2 = 23%) in the risk esti-
mates in the included studies. As shown in Fig. 2, comorbid
diabetes was found to be significantly associated with disease
severity or death of COVID-19 (pooled RR = 2.96 (95% CI: 2.31–
3.79; p < 0.001)). The shapes of Begg’s funnel plot did not
reveal evidence of obvious publication bias (Fig. 3). During.1 0.5 1 2 10
Risk Ratio RR (95% CI)
2.96 (2.31, 3.79)
2.85 (2.19, 3.71)
1.57 (0.46, 5.31)
3.96 (2.08, 7.54)
 5.14 (2.51, 10.5)
4.32 (2.41, 7.75)
1.44 (0.37, 5.63)
2.49 (1.62, 3.83)
0.84 (0.12, 5.94)
1.50 (0.43, 5.22)
tes with disease severity or death in COVID-19 patients. The
I, and the size of the grey squares reflects the relative weight
epresents the point estimate of risk ratio; the Y-axis
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 4 6 5the sensitivity analysis, the omission of any individual study
did not show a significant change in the pooled estimates (RR
ranged from 2.80 to 3.07).
4. Discussion
In this meta-analysis including nine original studies from dif-
ferent provinces/cities in China, we observed a positive asso-
ciation of diabetes with COVID-19 severity or mortality. It
indicated that patients with preexisting diabetes were at
higher risk of having worse outcome including severe
COVID-19 infection or death, compared to those without dia-
betes. A low level of statistical heterogeneity (I2 = 23%) and the
results of sensitivity analysis showed consistency across
studies.
Our findings are basically in agreement with a previous
meta-analysis [12], with similar estimated effect sizes. Nota-
bly, only one study [19] were included in both of the meta-
analyses. It indicates the necessity of our study due to the
quick update in literature regarding diabetes and COVID-19
during the ongoing pandemic. There were also several
meta-analyses [10,27–31] available regarding the diabetes
and disease severity. However, they did not specifically focus
on diabetes as a risk indicator, which could affect the eligibil-
ity criteria and therefore studies ought to be included. In addi-
tion, a nationwide data from the early phase of the epidemic
in China [4] reported that patients with diabetes had a 59%
increased risk of reaching to composite endpoints including
admission to ICU, or invasive ventilation, or death, after
adjustment for age and smoking status. The calculated RR
based on a study from Wuhan [32] was 1.94 (95% CI: 1.10–
3.39) comparing the mortality between diabetes patients
and their sex- and age-matched controls. It is understandable
that the adjusted estimate is lower than what we calculated,
which indicates the presence of confounding factors. Further-
more, our findings from China are essentially consistent with
the recent global data [33].
Indeed, patients with diabetes mellitus, especially type 2
diabetes, are more likely than others to develop severe infec-
tion. A higher risk of hospitalization and ICU admission after
pandemic influenza A (H1N1) infection has been reported [34].
Notably, diabetes is also a major contributor to worse progno-
sis in the previous epidemic coronavirus infections. Those
with preexisting diabetes had a higher risk of death than
those without the condition in patients with Middle East res-
piratory syndrome coronavirus (MERS-CoV) [35] and Severe
Acute Respiratory Syndrome (SARS) [36].
A variety of mechanisms have been suggested for
increased risk of disease severity or death associated with
comorbid diabetes [37]. Poor glycemic control leading to
immune dysfunction especially impaired T-cell response is
believed to play a pivotal role [38]. Other important mecha-
nisms may include chronic low-grade inflammation, down-
regulation of angiotensin converting enzyme 2 (ACE2), and
related comorbidities such as obesity, cardiovascular disease
and hypertension [5,39,40]. In addition, whether dipeptidyl
peptidase-4 (DPP-4) enzyme is involved in the link between
diabetes and the severity of COVID-19 remains unknown [2],
and further work is needed.The major strength of this study is the inclusion of geo-
graphically diverse samples to avoid potential overlapping
in patients. Moreover, we considered eligible studies in both
English and Chinese languages, which minimized the possi-
bility of missing any important findings relevant to this topic
in China. By integrating the currently best available data from
the country, our study provides more reliable estimates. How-
ever, the true association of diabetes with the risk of disease
severity or death has probably been overestimated. Due to
lack of information including demographic and clinical data,
we cannot examine to what extent diabetes independently
contributes to the increased risk. Ideally, a comprehensive
analysis of COVID-19 patients by diabetes status using nation-
wide original data with adequate consideration of confound-
ing should be conducted in order to better understand the
association.
To summarize, in this meta-analysis, we observed that
comorbid diabetes was associated with a nearly twofold
increased risk of having a greater disease severity or mortality
among COVID-19 patients in China. Our findings provide new
evidence that careful attention and medical intervention
should be given to patients with diabetes when facing the
COVID-19 pandemic.
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